LiveCare Inc. Announces Resolution of Investigation with the U.S. Department of Justice After Proactive Self-Disclosure
LiveCare Inc. (LVCE) has announced the resolution of a U.S. Department of Justice investigation regarding Anti-Kickback Statute and False Claims Act allegations. The investigation stemmed from a self-disclosure made by LiveCare in July 2023 after discovering potential non-compliance with Medicare rules for remote patient monitoring (RPM) services patient referrals.
The company conducted an internal investigation through external healthcare enforcement attorneys, which identified several risk areas requiring attention. LiveCare proactively disclosed these concerns about marketing practices to the U.S. Department of Health and Human Services Office of the Inspector General.
In response, LiveCare implemented corrective actions, including significant changes to patient acquisition methods and RPM service billing practices. CEO Max Rockwell emphasized the company's commitment to compliance and ethical business practices, highlighting the implementation of enhanced compliance measures to ensure continued operational integrity.
LiveCare Inc. (LVCE) ha annunciato la risoluzione di un'indagine del Dipartimento di Giustizia degli Stati Uniti riguardante le violazioni dello Statuto Anti-Kickback e della Legge sulle Falsi Dichiarazioni. L'indagine è nata da un'auto-segnalazione fatta da LiveCare nel luglio 2023, dopo aver scoperto potenziali non conformità con le normative Medicare relative ai rinvii dei pazienti per i servizi di monitoraggio remoto dei pazienti (RPM).
L'azienda ha condotto un'indagine interna tramite avvocati specializzati in enforcement sanitario esterni, che hanno identificato diverse aree di rischio che necessitano di attenzione. LiveCare ha proattivamente segnalato queste preoccupazioni riguardanti le pratiche di marketing all'Ufficio del Ispettore Generale del Dipartimento della Salute e dei Servizi Umani degli Stati Uniti.
In risposta, LiveCare ha implementato azioni correttive, compresi cambiamenti significativi nei metodi di acquisizione dei pazienti e nelle pratiche di fatturazione dei servizi RPM. Il CEO Max Rockwell ha sottolineato l'impegno dell'azienda per la conformità e le pratiche aziendali etiche, evidenziando l'implementazione di misure di conformità migliorate per garantire l'integrità operativa continua.
LiveCare Inc. (LVCE) ha anunciado la resolución de una investigación del Departamento de Justicia de EE. UU. sobre violaciones del Estatuto Anti-Kickback y la Ley de Falsas Declaraciones. La investigación surgió de una auto-disclosure realizada por LiveCare en julio de 2023 tras descubrir posibles incumplimientos con las normativas de Medicare en relación con las derivaciones de pacientes para los servicios de monitoreo remoto de pacientes (RPM).
La compañía llevó a cabo una investigación interna a través de abogados externos especializados en cumplimiento en salud, que identificaron varias áreas de riesgo que requieren atención. LiveCare comunicó proactivamente estas preocupaciones sobre las prácticas de marketing a la Oficina del Inspector General del Departamento de Salud y Servicios Humanos de EE. UU.
En respuesta, LiveCare implementó acciones correctivas, incluyendo cambios significativos en los métodos de adquisición de pacientes y en las prácticas de facturación de los servicios RPM. El CEO Max Rockwell enfatizó el compromiso de la compañía con el cumplimiento y las prácticas comerciales éticas, destacando la implementación de medidas de cumplimiento mejoradas para garantizar la integridad operativa continua.
LiveCare Inc. (LVCE)는 미국 법무부의 반부패법 및 허위청구법 관련 조사가 완료되었음을 발표했습니다. 이 조사는 2023년 7월 LiveCare가 원격 환자 모니터링(RPM) 서비스 환자 소개에 관한 Medicare 규정 위반의 가능성을 발견한 후 자발적으로 신고한 데서 시작되었습니다.
회사는 외부 의료 집행 변호사를 통해 내부 조사를 실시하였으며, 이에 따라 몇 가지 위험 영역이 발견되어 주의가 필요하다는 사실이 확인되었습니다. LiveCare는 이러한 마케팅 관행에 대한 우려를 미국 보건복지부 감사관실에 사전적으로 보고했습니다.
이에 대응하여 LiveCare는 환자 유치 방법과 RPM 서비스 청구 관행에 중대한 변경을 포함한 시정 조치를 시행하였습니다. CEO Max Rockwell은 회사의 준수와 윤리적인 비즈니스 관행에 대한 의지를 강조하며, 운영의 지속적인 무결성을 보장하기 위해 강화된 준수 조치를 시행했다고 말했습니다.
LiveCare Inc. (LVCE) a annoncé la résolution d'une enquête du ministère américain de la Justice concernant des allégations liées à la loi anti-kickback et à la loi sur les fausses déclarations. L'enquête a été déclenchée par une auto-dénonciation faite par LiveCare en juillet 2023, après la découverte de potentielles non-conformités aux règles de Medicare concernant les renvois de patients pour les services de surveillance à distance des patients (RPM).
La société a mené une enquête interne avec des avocats spécialisés en santé, qui ont identifié plusieurs domaines de risque nécessitant attention. LiveCare a proactivement signalé ces préoccupations concernant les pratiques de marketing au Bureau de l'Inspecteur général du ministère américain de la Santé et des Services sociaux.
En réponse, LiveCare a mis en œuvre des mesures correctives, y compris des changements significatifs dans les méthodes d'acquisition de patients et les pratiques de facturation des services RPM. Le PDG Max Rockwell a souligné l'engagement de la société envers la conformité et les pratiques commerciales éthiques, en mettant en avant la mise en place de mesures de conformité renforcées pour assurer l'intégrité opérationnelle continue.
LiveCare Inc. (LVCE) hat die Beendigung einer Untersuchung des US-Justizministeriums in Bezug auf Vorwürfe wegen Verstoßes gegen das Anti-Kickback-Gesetz und das Gesetz über falsche Ansprüche bekannt gegeben. Die Untersuchung resultierte aus einer Selbstmeldung, die LiveCare im Juli 2023 gemacht hatte, nachdem potenzielle Verstöße gegen die Medicare-Vorschriften für die Überweisungen von Patienten für Telemedizinanwendungen (RPM) entdeckt wurden.
Das Unternehmen führte eine interne Untersuchung mit externen Rechtsanwälten für Gesundheitsrecht durch, die mehrere Risikobereiche identifizierten, die einer näheren Betrachtung bedurften. LiveCare meldete proaktiv diese Bedenken bezüglich der Marketingpraktiken dem Büro des Generalinspektors des US-Gesundheitsministeriums.
Als Reaktion darauf implementierte LiveCare Korrekturmaßnahmen, die erhebliche Änderungen in den Methoden zur Patientenakquise und den Abrechnungspraktiken für RPM-Dienste umfassten. CEO Max Rockwell betonte das Engagement des Unternehmens für Compliance und ethische Geschäftspraktiken und hob die Einführung verbesserter Compliance-Maßnahmen hervor, um die kontinuierliche betriebliche Integrität zu gewährleisten.
- Proactive self-disclosure and cooperation with authorities demonstrates strong corporate governance
- Resolution of DOJ investigation removes regulatory uncertainty
- Implementation of enhanced compliance measures reduces future regulatory risks
- Identified non-compliance with Medicare rules could impact historical revenue
- Changes to marketing practices and billing systems may affect future revenue growth
- Potential reputational damage from regulatory investigation
Venice, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- LiveCare Inc. (OTCMKTS: LVCE), today announced the resolution of an investigation by the U.S. Department of Justice of allegations related to the Anti-Kickback Statute and the False Claims Act. The resolution was the result of a self-disclosure LiveCare made to the government in July 2023 and the company’s cooperation with the Department of Justice throughout its investigation.
- In early 2023, the Company learned that certain business practices may have been out of compliance with Medicare rules governing the referral of patients for remote patient monitoring (RPM) services. In response, LiveCare engaged external healthcare enforcement attorneys to conduct an internal investigation. This thorough review identified several areas of potential risk to be addressed to ensure full compliance with Medicare rules and applicable regulations. LiveCare promptly disclosed the matter to the U.S. Department of Health and Human Services Office of the Inspector General. The disclosure outlined concerns about the Company’s marketing practices. LiveCare also implemented a series of corrective actions aimed at improving its operations. These efforts included significant enhancements and changes to the way the company acquires patients and bills for its RPM services.
“At LiveCare, we take compliance very seriously,” said Max Rockwell, CEO of LiveCare Inc. “When we identified areas where we fell short, we took immediate and transparent action by reporting the issues to the government and working diligently to implement necessary corrective measures. Our priority is always the wellbeing of our patients, and we have enhanced our internal compliance practices to monitor compliance with the law.”
“We understand that trust is essential in healthcare, and our commitment to ethical business practices is unwavering,” Rockwell added. “In addition to fully cooperating with the Department of Justice and relevant authorities, we have implemented a comprehensive set of enhanced compliance measures. These steps will ensure that we continue to operate with the utmost integrity, providing the highest level of care to our patients.”
About LiveCare
LiveCare remains committed to providing high-quality remote patient monitoring services to individuals with chronic conditions, including Type 2 diabetes. The company’s patient-centered approach leverages innovative technology to improve health outcomes and empower patients to manage their conditions more effectively. LiveCare’s dedication to enhancing the patient experience is at the core of its mission and will continue to guide the company as it moves forward.
Contact:
Investor Relations Department
Phone: (941) 225-6699
Email: public-relations@livecarehealth.com
FAQ
What triggered the DOJ investigation of LiveCare (LVCE) in 2023?
What changes did LiveCare (LVCE) implement following the investigation?
How did LiveCare (LVCE) handle the Medicare compliance issues discovered in 2023?
What areas of LiveCare's (LVCE) business were affected by the compliance review?
